New data shows benefit of drug combination for metastatic castration resistant prosta

[News]

New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer (mCRPC).

More... (https://www.news-medical.net/news/20210918/New-data-shows-benefit-of-drug-combination-for-metastatic-castration-resistant-prostate-cancer.aspx)